Kadmon Holdings Inc. (KDMN) |
|
3.76 -0.04 (-1.05%)
|
09-29 08:55 |
|
Open: |
3.83 |
Pre. Close: |
3.8 |
|
High:
|
3.85 |
Low:
|
3.7 |
|
Volume:
|
1,930,087 |
Market Cap:
|
643M |
|
|
|
|
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company is headquartered in New York City, New York and currently employs 116 full-time employees. The firm is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The firm's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.841 - 3.862 |
3.862 - 3.879 |
|
Low:
|
3.635 - 3.665 |
3.665 - 3.689 |
|
Close:
|
3.716 - 3.76 |
3.76 - 3.797 |
|
Technical analysis |
as of: 2020-09-28 4:34:28 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 5.28 One year: 5.89 |
| Support: |
Support1: 3.69 Support2: 3.07 |
| Resistance: |
Resistance1: 4.52 Resistance2: 5.04 |
| Pivot: |
4.18 |
| Moving Average: |
MA(5): 3.89 MA(20): 4.26
MA(100): 4.38 MA(250): 4.17  |
| MACD: |
MACD(12,26): -0.12 Signal(9): -0.04 |
| Stochastic oscillator: |
%K(14,3): 9.54 %D(3): 10.52 |
| RSI: |
RSI(14): 35.34 |
| 52-week: |
High: 5.50 Low: 2.30 Change(%): 46.3 |
| Average Vol(K): |
3-Month: 235014 10-Days: 272040 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.KDMN has closed above bottom band by 9.8%. Bollinger Bands are 20% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 28 Sep 2020
When is Kadmon Holdings, Inc. (KDMN) going to be good investment? - Marketing Sentinel
Mon, 28 Sep 2020
Kadmon Holdings Inc. (KDMN) upgraded Issued by Wall Street Gurus - The News Heater
Thu, 24 Sep 2020
Will Short Term Positive News Increase The Share Price Of Kadmon Holdings, Inc. (KDMN)? - Invest Million
Wed, 23 Sep 2020
Kadmon Holdings Inc. (KDMN) is 1.08% away from 50-day simple Moving Average despite all headwinds - News Daemon
Wed, 23 Sep 2020
Looking Closely at the Growth Curve for Kadmon Holdings Inc. (KDMN) - The News Heater
Tue, 22 Sep 2020
Is Kadmon Holdings Inc (KDMN) a Winner in the Biotechnology Industry? - InvestorsObserver
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
171 |
| Shares Float (M) |
139 |
|
% Held by Insiders
|
0.16 |
|
% Held by Institutions
|
83.14 |
|
Shares Short (K)
|
27,090 |
|
Shares Short P. Month (K)
|
28,420 |
Stock Financials |
|
EPS
|
-0.892 |
|
EPS Est This Year
|
-1.550 |
|
EPS Est Next Year
|
-1.750 |
|
Book Value (p.s.)
|
0.700 |
|
Profit Margin
|
|
|
Operating Margin
|
-715.86 |
|
Return on Assets (ttm)
|
-24.6 |
|
Return on Equity (ttm)
|
-85.8 |
|
Qtrly Rev. Growth
|
853.8 |
|
Gross Profit (p.s.)
|
0.022 |
|
Sales Per Share
|
0.069 |
|
EBITDA (p.s.)
|
-0.486 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-74 |
|
Levered Free Cash Flow (M)
|
-38 |
Stock Valuations |
|
PE Ratio
|
-4.22 |
|
PEG Ratio
|
|
|
Price to Book value
|
5.37 |
|
Price to Sales
|
54.49 |
|
Price to Cash Flow
|
-8.73 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
